Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

A recent decision by USDA could pave the way for an H5N1 avian flu vaccine for dairy cows by as early as the first quarter of ...

Merck Animal Health recently awarded $90,000 in scholarships to nine aspiring bovine veterinarians in collaboration with the ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese's candy, call himself an 'old fart' when asked about career plans, get real about the ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.